Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches
Authors
Keywords
Ovarian cancer, Targeted therapy, Angiogenesis, Anti-vascular agent, Resistance to anti-VEGF therapy
Journal
CANCER AND METASTASIS REVIEWS
Volume 34, Issue 1, Pages 19-40
Publisher
Springer Nature
Online
2014-12-29
DOI
10.1007/s10555-014-9538-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503)
- (2013) S Sahebjam et al. BRITISH JOURNAL OF CANCER
- Integrated Analyses Identify a Master MicroRNA Regulatory Network for the Mesenchymal Subtype in Serous Ovarian Cancer
- (2013) Da Yang et al. CANCER CELL
- Synaptojanin-2 Binding Protein Stabilizes the Notch Ligands DLL1 and DLL4 and Inhibits Sprouting Angiogenesis
- (2013) M. Gordian Adam et al. CIRCULATION RESEARCH
- A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer
- (2013) Joyce F. Liu et al. EUROPEAN JOURNAL OF CANCER
- A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma
- (2013) Thomas J. Herzog et al. GYNECOLOGIC ONCOLOGY
- A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: A Gynecologic Oncology Group study
- (2013) Lainie P. Martin et al. GYNECOLOGIC ONCOLOGY
- A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors
- (2013) Ivan Diaz-Padilla et al. INVESTIGATIONAL NEW DRUGS
- Randomized Phase III Study of Erlotinib Versus Observation in Patients With No Evidence of Disease Progression After First-Line Platin-Based Chemotherapy for Ovarian Carcinoma: A European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup Study
- (2013) Ignace B. Vergote et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy
- (2012) K. H. Baumann et al. ANNALS OF ONCOLOGY
- A Phase I Trial of Dasatinib, an Src-Family Kinase Inhibitor, in Combination with Paclitaxel and Carboplatin in Patients with Advanced or Recurrent Ovarian Cancer
- (2012) A. A. Secord et al. CLINICAL CANCER RESEARCH
- Phase I Trial of Combretastatin A4 Phosphate (CA4P) in Combination with Bevacizumab in Patients with Advanced Cancer
- (2012) P. Nathan et al. CLINICAL CANCER RESEARCH
- A phase II study of RO4929097 in metastatic colorectal cancer
- (2012) Jonathan R. Strosberg et al. EUROPEAN JOURNAL OF CANCER
- Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study
- (2012) Russell J. Schilder et al. GYNECOLOGIC ONCOLOGY
- A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma
- (2012) Susana M. Campos et al. GYNECOLOGIC ONCOLOGY
- Phase I Study of RO4929097, a Gamma Secretase Inhibitor of Notch Signaling, in Patients With Refractory Metastatic or Locally Advanced Solid Tumors
- (2012) Anthony W. Tolcher et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer
- (2011) M. Zweifel et al. ANNALS OF ONCOLOGY
- Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179)
- (2011) C. Kollmannsberger et al. ANNALS OF ONCOLOGY
- The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis
- (2011) Weon-Kyoo You et al. BMB Reports
- Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients
- (2011) Denis Lane et al. BMC CANCER
- Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer
- (2011) F A Raja et al. BRITISH JOURNAL OF CANCER
- A Dynamic Inflammatory Cytokine Network in the Human Ovarian Cancer Microenvironment
- (2011) H. Kulbe et al. CANCER RESEARCH
- Biological Roles of the Delta Family Notch Ligand Dll4 in Tumor and Endothelial Cells in Ovarian Cancer
- (2011) W. Hu et al. CANCER RESEARCH
- Beyond VEGF: Inhibition of the Fibroblast Growth Factor Pathway and Antiangiogenesis
- (2011) C. Lieu et al. CLINICAL CANCER RESEARCH
- Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer
- (2011) Jermaine Coward et al. CLINICAL CANCER RESEARCH
- A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer
- (2011) Katherine M. Bell-McGuinn et al. GYNECOLOGIC ONCOLOGY
- Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: A phase II study
- (2011) Lubomir Bodnar et al. GYNECOLOGIC ONCOLOGY
- Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group
- (2011) R. Ramasubbaiah et al. GYNECOLOGIC ONCOLOGY
- Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: A Gynecologic Oncology Group study
- (2011) Kian Behbakht et al. GYNECOLOGIC ONCOLOGY
- Influence of the vascular damaging agents DMXAA and ZD6126 on hypericin distribution and accumulation in RIF-1 tumors
- (2011) Thierry Marysael et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor–resistant human lung adenocarcinoma
- (2011) Tina Cascone et al. JOURNAL OF CLINICAL INVESTIGATION
- Randomized Phase II Placebo-Controlled Trial of Maintenance Therapy Using the Oral Triple Angiokinase Inhibitor BIBF 1120 After Chemotherapy for Relapsed Ovarian Cancer
- (2011) Jonathan A. Ledermann et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer
- (2011) Beth Y. Karlan et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular mechanisms and clinical applications of angiogenesis
- (2011) Peter Carmeliet et al. NATURE
- Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases
- (2011) Peter Carmeliet et al. NATURE REVIEWS DRUG DISCOVERY
- Endothelial α3β1-Integrin Represses Pathological Angiogenesis and Sustains Endothelial-VEGF
- (2010) Rita Graça da Silva et al. AMERICAN JOURNAL OF PATHOLOGY
- A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study
- (2010) J. J. Biagi et al. ANNALS OF ONCOLOGY
- Double Antiangiogenic Protein, DAAP, Targeting VEGF-A and Angiopoietins in Tumor Angiogenesis, Metastasis, and Vascular Leakage
- (2010) Young Jun Koh et al. CANCER CELL
- HGF/c-Met Acts as an Alternative Angiogenic Pathway in Sunitinib-Resistant Tumors
- (2010) F. Shojaei et al. CANCER RESEARCH
- Effects of Siltuximab on the IL-6-Induced Signaling Pathway in Ovarian Cancer
- (2010) Y. Guo et al. CLINICAL CANCER RESEARCH
- A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies
- (2010) Sarah M. Temkin et al. GYNECOLOGIC ONCOLOGY
- A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer
- (2010) Michael Friedlander et al. GYNECOLOGIC ONCOLOGY
- Regulation of the expression balance of angiopoietin-1 and angiopoietin-2 by Shh and FGF-2
- (2010) Takaaki Fujii et al. IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL
- Sorafenib in Combination With Gemcitabine in Recurrent Epithelial Ovarian Cancer
- (2010) Stephen A. Welch et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Activity of Sorafenib in Recurrent Ovarian Cancer and Primary Peritoneal Carcinomatosis: A Gynecologic Oncology Group Trial
- (2010) Daniela Matei et al. JOURNAL OF CLINICAL ONCOLOGY
- Differential Phosphoproteomics of Fibroblast Growth Factor Signaling: Identification of Src Family Kinase-Mediated Phosphorylation Events
- (2010) Debbie L. Cunningham et al. JOURNAL OF PROTEOME RESEARCH
- Asymmetric tyrosine kinase arrangements in activation or autophosphorylation of receptor tyrosine kinases
- (2010) Jae Hyun Bae et al. MOLECULES AND CELLS
- Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
- (2010) Mark E. Davis et al. NATURE
- Pericytes: Blood-Brain Barrier Safeguards against Neurodegeneration?
- (2010) Annelies Quaegebeur et al. NEURON
- Cell delivery of Met docking site peptides inhibit angiogenesis and vascular tumor growth
- (2010) A R Cantelmo et al. ONCOGENE
- Contrasting Actions of Selective Inhibitors of Angiopoietin-1 and Angiopoietin-2 on the Normalization of Tumor Blood Vessels
- (2009) Beverly L. Falcón et al. AMERICAN JOURNAL OF PATHOLOGY
- All-in-One Target-Cell-Specific Magnetic Nanoparticles for Simultaneous Molecular Imaging and siRNA Delivery
- (2009) Jae-Hyun Lee et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Endothelial-Mural Cell Signaling in Vascular Development and Angiogenesis
- (2009) Konstantin Gaengel et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Cross-talk between the VEGF-A and HGF signalling pathways in endothelial cells
- (2009) Eric Sulpice et al. BIOLOGY OF THE CELL
- PDGF-C Mediates the Angiogenic and Tumorigenic Properties of Fibroblasts Associated with Tumors Refractory to Anti-VEGF Treatment
- (2009) Yongping Crawford et al. CANCER CELL
- Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases
- (2009) F. Qian et al. CANCER RESEARCH
- E7050: A dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models
- (2009) Takayuki Nakagawa et al. CANCER SCIENCE
- NK4, an HGF antagonist, prevents hematogenous pulmonary metastasis by inhibiting adhesion of CT26 cells to endothelial cells
- (2009) Takeshi Kubota et al. CLINICAL & EXPERIMENTAL METASTASIS
- Combined Inhibition of Vascular Endothelial Growth Factor and Epidermal Growth Factor Signaling in Non–Small-Cell Lung Cancer Therapy
- (2009) Suchita Pakkala et al. Clinical Lung Cancer
- The tumor-promoting actions of TNF-α involve TNFR1 and IL-17 in ovarian cancer in mice and humans
- (2009) Kellie A. Charles et al. JOURNAL OF CLINICAL INVESTIGATION
- Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer
- (2009) Ursula A. Matulonis et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety, Pharmacokinetics, and Antitumor Activity of AMG 386, a Selective Angiopoietin Inhibitor, in Adult Patients With Advanced Solid Tumors
- (2009) Roy S. Herbst et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance
- (2009) Scott Kopetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Nanomedicine based approaches for the delivery of siRNA in cancer
- (2009) B. Ozpolat et al. JOURNAL OF INTERNAL MEDICINE
- The FGF family: biology, pathophysiology and therapy
- (2009) Andrew Beenken et al. NATURE REVIEWS DRUG DISCOVERY
- Control of vascular morphogenesis and homeostasis through the angiopoietin–Tie system
- (2009) Hellmut G. Augustin et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma
- (2009) R. C. Kane et al. ONCOLOGIST
- Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs
- (2008) R Bianco et al. BRITISH JOURNAL OF CANCER
- Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis
- (2008) Daniela Matei et al. CANCER
- Loss of E-Cadherin Promotes Ovarian Cancer Metastasis via 5-Integrin, which Is a Therapeutic Target
- (2008) K. Sawada et al. CANCER RESEARCH
- Induction of hepatocyte growth factor activator gene expression under hypoxia activates the hepatocyte growth factor/c-Met system via hypoxia inducible factor-1 in pancreatic cancer
- (2008) Yoshihiko Kitajima et al. CANCER SCIENCE
- Eph-Ephrin Bidirectional Signaling in Physiology and Disease
- (2008) Elena B. Pasquale CELL
- Role of platelet-derived growth factors in physiology and medicine
- (2008) J. Andrae et al. GENES & DEVELOPMENT
- Angiogenesis as a strategic target for ovarian cancer therapy
- (2008) Whitney A Spannuth et al. Nature clinical practice. Oncology
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More